Assembly Biosciences Doses First Two Participants in Phase 2 Study of Oral NTCP Inhibitor ABI-6250 for Chronic Hepatitis Delta Virus
Assembly Biosciences dosed the first two participants in a Phase 2 study of ABI-6250, its investigational oral NTCP inhibitor for chronic hepatitis delta virus infection. The multicenter, open-label study (NCT07762027) will enroll approximately 80 participants across two once-daily oral dose levels, evaluating safety, PK, and antiviral activity, with initial data expected in the fourth quarter of 2027. Under Assembly Bio's 12-year collaboration with Gilead Sciences, Gilead can license ABI-6250 through Phase 2 completion for a $90 million opt-in fee, providing a clear strategic and financial path for the asset.
Key figures
- Drug Name
- ABI-6250
- Phase Of Trial
- Phase 2
- Gilead opt in fee
- $90 million
- Phase1a half life
- ~4 days
- Expected enrollment
- ~80 participants with chronic HDV
- Initial data timing
- Q4 2027
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.